Trial
NCT02719990
Open-label Extension Study to Evaluate the Safety of Long-term Twice-monthly Administration of Somavaratan in Adult Growth Hormone Deficiency (AGHD)
Phase IITERMINATEDEFFICACY/FUTILITYConfidence: HIGH
Sponsor
Versartis Inc.
Collaborators
—
Condition
Adult Growth Hormone Deficiency (AGHD)
Intervention
somavaratan
Why stopped
Phase 3 clinical trial of somavaratan in pediatric growth hormone deficiency (PGHD) did not meet its primary endpoint of non-inferiority.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2023-04-13